Denali Therapeutics Inc.

Genentech, Inc.

F. Hoffmann-La Roche Ag

Jianwen A Feng

Anthony A Estrada

Javier De Vicente Fidalgo

Zachary Kevin Sweeney

Brian M Fox

Joseph P Lyssikatos

Maksim Osipov

Colin Philip Leslie

Arun Thottumkara

Robert A Craig, Ii

Cheng Hu

Alfonso Pozzan

Christopher R H Hale

Cinzia Maria Francini

Anantha R Sudhakar

Aleksandr Kolesnikov

Steven T Staben

Giorgio Bonanomi

Katrina W Lexa

Georgette M Castanedo

James John Crawford

Travis Remarchuk

Christian A G N Montalbetti

Elena Serra

Jun Liang

Alan G Olivero

Po-wai Yuen

Chudi Obioma Ndubaku

Nicole Blaquiere

Pui Leng Loke

Naomi S Rajapaksa

Jason Burch

Guosheng Wu

Joy Drobnick

Marian C Bryan

Alberto Gobbi

Baihua Hu

James Richard Kiefer, Jr

Carmela Napolitano

Federica Tonelli

Colin Phillip Leslie

Robert A Ii Craig

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Compounds, compositions and methods

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.

LRRK2 inhibitors and methods of making and using thereof

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.

The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Kinase inhibitors and uses thereof

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

Modulators of eukaryotic initiation factor 2B, compositions and methods

The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.

Substituted pyrimidines as LRKK2 inhibitors

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Compounds, compositions, and methods

Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.

Compound, compositions, and methods

Growing community of inventors

San Mateo, CA, United States of America

Jianwen A Feng